ClinicalTrials.Veeva

Menu

Hydrochlorothiazide (+) Losartan Potassium vs. Amlodipine Comparative Study (0954A-314)

Organon logo

Organon

Status and phase

Completed
Phase 4

Conditions

Essential Hypertension

Treatments

Drug: MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks

Study type

Interventional

Funder types

Industry

Identifiers

NCT00157963
2005_067
0954A-314

Details and patient eligibility

About

An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension

Enrollment

174 patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients of age 20 70 75 with essential hypertension
  • SiDBP 90 ~ 114mmHg at V1 & V2

Exclusion criteria

  • Patient has known or suspected secondary hypertension
  • Patient has a history of malignant hypertension (SiSBP > 210mmHg)
  • Individuals has a known sensitivity or intolerance to HCTZ or any AIIAs, or any sulfonamide-derived drugs.
  • Patient has shown significant abnormal laboratory evaluations

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems